Stockwinners Market Radar for August 03, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EDT Cathie Wood's ARK Investment bought 68K shares of Markforged today

19:48 EDT Biogen, Eisai present new findings on lecanemab - Eisai Co. (ESALY) and Biogen (BIIB) announced that Eisai presented new findings on a subcutaneous formulation of lecanemab, or BAN2401, and the modeling simulation of the impact of ApoE4 genotype on the incidence of amyloid-related imaging abnormalities - edema/effusion - in subjects treated with lecanemab, an investigational anti-amyloid beta protofibril antibody for the treatment of mild cognitive impairment due to Alzheimer's disease and mild AD with confirmed presence of amyloid pathology in the brain. The data were shared at the Alzheimer's Association International Conference in San Diego, CA. Eisai Abstract #69438: This Phase 1 study was an open-label, parallel-group study conducted in healthy subjects: 30 subjects were randomized into a 10 mg/kg intravenous (IV) dose group and 29 subjects were randomized into a single fixed 700mg SC dose group. The absolute bioavailability of lecanemab following a single SC injection was 49.7%. After SC dosing, the Cmax was observed 72 hours post-dose and was 4-fold lower compared to IV infusion, which reflects the relatively long absorption phase following SC dose administration compared with 1-hour IV infusion. Lecanemab's half-life (~7 days) was similar following SC and IV administrations. The incidence of adverse events was similar between SC and IV administrations. No positive results for neutralizing antibodies (NAb) were recorded in this study. Lecanemab PK for the 5 Japanese subjects was similar to that of the non-Japanese subjects following a single subcutaneous dose administration. Eisai Abstract #69429: In this analysis, modeling and simulation was conducted to evaluate the equivalence of a fixed weekly SC dose to a body weight-based 10 mg/kg IV bi-weekly dose with regard to lecanemab exposure. The analysis showed that a fixed lecanemab SC dose of 720 mg administered weekly may potentially result in comparable exposure (AUC) and efficacy as measured by reduction in amyloid PET SUVr to 10mg/kg IV dose administered bi-weekly. The exposure-response model is based on the established correlation between ARIA-E and Cmax. SC lecanemab dose is predicted to have a lower incidence of ARIA-E compared to IV lecanemab due to lower Cmax following SC administration.

18:26 EDT LGI Homes reports 469 homes closed in July - LGI Homes "announced it closed 469 homes in July 2022. As of July 31, 2022, the Company had 93 active selling communities."

18:21 EDT Jakks Pacific holder Benefit Street Partners sells $16M in common stock - Benefit Street Partners disclosed sale of 700K share of Jakks Pacific common stock on July 28th in a total transaction size of $16M. Shares of Jakks Pacific are down 1.9% afterhours.

17:59 EDT Bill & Melinda Gates Foundation disclose 15.8% LumiraDx stake in 13D filing - The "purpose of the Foundation's investments in the Issuer is to further its charitable purpose of, among other things, accelerating the development of lifesaving and low-cost diagnostics to reduce the burden of diseases in low and middle income countries by securing global access commitments in respect of availability and affordability of new, low-cost products and services developed through the use of the Issuer's capabilities, including in respect of diagnostic tests, integrated point-of-care (POC) diagnostic platforms and connected health IT and care solutions. The Foundation has worked with the Issuer with the goal of achieving the following key objectives: developing assays with significant potential to improve global health, including a test for HIV viral load; accelerating development of the Issuer's next-generation instrument that is low-cost, robust and appropriate for all clinical settings, globally; and supporting local healthcare delivery partners in Foundation-priority markets to incorporate the potential of the Issuer's technology into high-impact, low-cost disruptive diagnostic treatment models." Shares of LumiraDX are up 7.9% afterhours.

17:53 EDT Microsoft testing PC Game Pass widget on Windows 11 - Microsoft said in a blog post that it is releasing Windows 11 Insider Preview Build 25174 to the Dev Channel, with the company noting that it is previewing the new Game Pass widget with Windows Insiders in the Dev Channel. "PC Game Pass and Windows are a fantastic combination for gaming; with PC Game Pass, you have access to hundreds of high-quality games for your PC," the company said. "For the past couple of months, we've been working with our friends on the Xbox team to make Windows and PC Game Pass an even better combination; today we're announcing something new for gaming and our widgets experience: the Game Pass widget preview. This widget is a window to the extensive PC Game Pass library - it will show the latest additions, games leaving soon, and others from highlighted categories and then take you to the Xbox app where you can install them, see reviews, and go all in. We're still hard at work on some exciting functionality coming soon that will let you sign-into your Xbox profile and easily jump back into recently played games as well as see personalized recommendations of games we believe you'll love."

17:42 EDT Surgalign reaches settlement with U.S. SEC, to pay civil penalty of $2M - Surgalign Holdings reached a settlement with the U.S. SEC on August 3, concluding and resolving in its entirety the previously disclosed SEC investigation relating to activities that occurred between 2015 and 2019 by RTI Surgical Holdings, Inc., and RTI Surgical, Inc. and the prior management. As reflected in the SEC's Order, those activities included pulling sales forward from future quarters to address projected quarterly revenue shortfalls. Under the terms of the settlement, the company has agreed to pay a civil penalty of $2M which was recorded in full during the fourth quarter of 2021. As part of the settlement, the company has also agreed to refrain from future violations of specified provisions of federal securities laws and rules. In addition to the settlement, the company is expected to receive $0.6M from former executives related to recouped compensation. The SEC acknowledged that in assessing Surgalign's offer of settlement, it took into consideration its substantial cooperation with the Commission's staff throughout the investigation, including by disclosing information about conduct that the staff had not yet uncovered through its own investigation, conducting an internal investigation regarding this conduct, and providing the staff regular and detailed updates on the internal investigation and key documents identified through that investigation.

17:28 EDT Raytheon Technologies awarded $96.2M U.S. Navy contract - Raytheon Missile & Defense is awarded a $96,177,767 cost-plus-fixed-fee definitization modification to a previously awarded undefinitized contract action for maintenance & recertifications in support of the Evolved SeaSparrow Missile and NATO SeaSparrow Missile Systems programs. If all options are exercised, work will continue through December 2025.

17:23 EDT Sun Life Financial appoints Chris Wei Chief Client and Innovation Officer - Sun Life announced the appointment of Chris Wei as executive VP and Chief Client and Innovation Officer. Wei brings more than 25 years of global leadership experience in insurance and wealth management and will be a member of Sun Life's Executive Team. In this newly created role, Wei will be responsible for leading the company's commitment to Client experience excellence. The Chief Sustainability Officer, Chief Marketing Officer and head of Corporate Communications will report to Wei. Combined, these teams will aim to "strategically position Sun Life as a sustainability-driven, Client-centered and people-first global brand." Wei will also be responsible for "identifying and cultivating innovative solutions focused on achieving our Purpose, including the establishment of measurable targets in helping our Clients achieve lifetime financial security and live healthier lives, whilst maximising our impact to foster a sustainable society and healthier planet."

17:14 EDT Aris Water Solutions acquires all of Delaware Energy's assets - The company said: "On August 1, 2022, we acquired all of Delaware Energy's assets in exchange for 3.37 million Class A shares and a small, volumetric-based contingent consideration paid over 5 years. Delaware Energy's assets include seven produced water handling facilities and associated gathering lines in Aris's core areas of Eddy and Lea County, New Mexico. Once integrated, these assets will allow Aris to bring additional water volumes into its network, enhance its recycling capabilities, and further accelerate its organic growth."

17:09 EDT FleetCor extends BP relationship - FleetCor (FLT) announced that it has extended its agreement to manage the commercial fleet card program for BP (BP). FleetCor will continue to operate BPs commercial fleet card program across more than 6,500 North America locations. "We're delighted that BP North America has entrusted us with their fleet card program for an extended term. It reinforces that BP is pleased with our performance and with our plans for the program going forward. We couldn't be happier," said Ron Clarke, chairman and chief executive officer, FleetCor Technologies.

16:51 EDT Essential Utilities sees long-term EPS CAGR of 5%-7% for 2021-2024

16:51 EDT Essential Utilities boosts dividend 7% to 28.7c per share - On Aug. 2, 2022, Essential's board of directors declared a quarterly cash dividend of $0.2870 per share of common stock. This represents a 7% increase to the quarterly dividend rate and is the company's 32nd increase in the last 31 years. This dividend will be payable on Sept. 1, 2022 to shareholders of record on Aug. 12, 2022. The company has paid a consecutive quarterly cash dividend for 77 years.

16:47 EDT Terreno Realty raises quarterly dividend 17.6% to 40c per share - Terreno Realty declared a regular cash dividend for the quarter ending September 30, 2022 of $0.40 per common share; an increase of 17.6% over the prior dividend level. The dividend will be payable on October 14, 2022 to common stockholders of record at the close of business on September 30, 2022.

16:46 EDT Gamco Investors adds Doug Jamieson to Office of the CEO - GAMCO Investors announced that it has created an Office of the CEO, and added Doug Jamieson to the role. Commenting on the addition, Mario Gabelli, Chair stated, "I am pleased to have Doug Jamieson join me in the Office of the CEO. His forty years of experience with GAMCO will continue to benefit all of our clients, teammates and stakeholders."

16:44 EDT Tenaris anticipates further growth in sales, stable margins in second half - The company said, "Even as global economic growth slows and central banks raise interest rates to contain inflationary pressures, prices for oil and gas remain high and prices for gas and electric energy in Europe have reached unprecedented levels. The Ukraine war drags on and the impact of further sanctions on Russian oil exports as well as reductions in flows of Russian gas to Europe have increased market uncertainty. Inventories remain at low levels and the supply response remains limited reflecting low investment levels over the past years and uncertainty about longer-term demand in the energy transition. Drilling activity continues to increase around the world led by North America and the Middle East. Offshore drilling activity is increasing with deepwater developments in Brazil, Guyana and sub-Saharan Africa. Pipeline project activity is advancing in the Middle East and South America. In the second half, we anticipate further growth in sales and stable margins, with higher prices compensating cost increases. Growth in sales will be more limited in the third quarter as they will be affected by seasonal factors and lower shipments to pipeline projects. We also anticipate that free cash flow will remain positive during the semester."

16:42 EDT Signify Health sees FY HCS revenue $800M-$810M - For FY22, the company sees: Caravan Health revenue in the range of $45 million to $48 million for the 10-month period following the acquisition; Adjusted EBITDA margin for HCS and Caravan Health of 29% to 30%, which is before shared costs that are currently allocated to the company's ECS segment; Of the $60 million in annualized shared costs that are currently allocated to the ECS segment, the Company continues to expect to eliminate approximately $30 million to $35 million in annualized expenses by the end of 2022. The Company is not providing guidance for the Episodes business that it is in the process of winding down.

16:40 EDT Warrior Met Coal backs FY22 coal sales view of 5.5M-6.5M short tons - Backs FY22 coal production view of 5.5M-6.5M short tons and raises capex to $185M-$200M from $165M-$175M.

16:35 EDT Sutter Rock Capital trading resumes

16:34 EDT AAR Corp. awarded $173.5M firm-fixed-price contract from U.S. Air Force - AAR CORP. has been awarded a firm-fixed-price requirements contract from the U.S. Air Force to produce Next Generation All Aluminum Cargo Pallets. The basic contract period of performance is for 18 months with eight 12 month options and one 6 month option. The total contract value including option periods is $173.5M.

16:32 EDT Coeur Mining backs FY22 gold production 100K-110K ounces - Full-year 2022 production is expected to be 100,000 - 110,000 ounces of gold and 6.0 - 7.0 million ounces of silver. CAS in 2022 are expected to be $825 - $925 per gold ounce (previously $750 - $850 per ounce) and $12.75 - $13.75 per silver ounce (previously $13.50 - $14.50 per ounce). The revised figures largely reflect an anticipated change in the allocation of costs on a co-product basis. Capital expenditures are expected to be $48 - $53 million (previously $50 - 55 million). The revised figure is based on timing of projects in 2022.

16:28 EDT Bio-Rad acquires Curiosity Diagnostics for total consideration of up to $170M - Bio-Rad Laboratories announced that it has reached an agreement to acquire all of the outstanding shares of Curiosity Diagnostics, Sp. Z. o. o. from Scope Fluidics, a Warsaw, Poland, based developer of innovative technology solutions for the medical diagnostic and healthcare markets, for a total consideration of up to $170 million, consisting of approximately $100 million in cash, and up to $70 million in future milestone payments. Curiosity Diagnostics, a late-stage, pre-commercial platform company, is in the process of developing a sample-to-answer, rapid diagnostics PCR system for the molecular diagnostics market. "We are excited to have the Curiosity Diagnostics team join Bio-Rad's Clinical Diagnostics Group and to work closely together to bring a new generation of rapid PCR systems to market," said Dara Wright, Bio-Rad's EVP and President, Clinical Diagnostics Group. "Curiosity's PCR platform, PCR ONE, offers a streamlined workflow and rapid turnaround times, and is expected to extend our reach beyond high-complexity labs into near-patient molecular diagnostics labs."

16:26 EDT Northern Oil and Gas updating production expense guidance - "NOG increased production and capital expenditure guidance on June 7, 2022, with the announcement of its pending Williston Basin acquisition. NOG is updating production expense guidance to account for higher processing costs associated with higher than expected NGL prices received year-to-date. Additionally, production expense guidance has been adjusted to reflect slightly higher operating costs on the properties from the pending Williston acquisition versus NOG's corporate average. The higher than expected gas realizations year-to-date from higher NGL prices, as well as better realized oil prices in both the Williston and Permian basins, have led to improved annual guidance for oil differentials and gas realizations," the company said.

16:25 EDT RPT Realty acquires Mary Brickell Village in Miami - RPT Realty announced the acquisition of Mary Brickell Village, or MBV, in Miami, through the company's grocery-anchored joint venture platform, for a contract price of $216M, or $111M at the company's pro-rata share. MBV is a generational three-story, 200,000 square foot, grocery anchored, mixed-use center that sits on 5.2 acres in Miami's Brickell neighborhood.

16:24 EDT FleetCor acquires Accrualify, terms not stated - FLEETCOR "announced it has acquired Accrualify, Inc., an accounts payable (AP) automation software company. The Accrualify acquisition strengthens FLEETCOR(R)'s portfolio of payments solutions and rounds out its corporate payments platform capabilities. Accrualify's technology helps companies automate every step of the procure-to-pay (P2P) process, from purchase request to payment. The comprehensive, cloud-based software platform provides middle market companies full end-to-end procurement and invoice process automation as well as payments execution."

16:23 EDT Inari Medical announces COO Hykes to succeed Hoffman as CEO - Inari Medical announced that Chief Operating Officer, COO, Drew Hykes will succeed Bill Hoffman as Chief Executive Officer, CEO, effective January 1, 2023. Hykes will join Inari's Board of Directors and Hoffman will also continue to serve on the Board. Hykes joined Inari in 2017 as Chief Commercial Officer and has served as the Company's Chief Operating Officer since 2020.

16:21 EDT Fisker sees FY22 CapEx $280M-$290M

16:20 EDT Royal Gold backs guidance for sales of 315,000 to 340,000 GEOs - "There is no change to previously issued guidance for sales of 315,000 to 340,000 GEOs, depreciation, depletion and amortization expense of $535 to $585 per GEO, and an effective tax rate of 17% to 22% for 2022. Due to uncertainty with respect to the timing and amount of the first payment from the Cortez Royalty described above, 2022 guidance ranges were not adjusted to include any contribution from this royalty at this time. Royal Gold has two near term financing commitments which the Company expects to pay using available cash. The first is the potential payment of C$199.5 million (approximately $155 million) for the acquisition of GBR upon closing of that transaction, which is expected in the third quarter subject to receipt of all necessary approvals. The second is the potential payment of up to $6.8 million to a subsidiary of Ero Copper Corporation for the achievement of success-based targets related to regional exploration and mineral resource targets under the NX Gold stream, which may occur at any time prior to the end of 2024," the company said.

16:18 EDT MGM Resorts repurchased over $1.1B of company stock in Q2

16:16 EDT Lumen reiterates FY22 financial outlook

16:14 EDT Clorox announces streamlined operating model - As part of its journey to Reimagine Work - one of the key pillars of its IGNITE strategy - Clorox is announcing a streamlined operating model to create a simpler, faster company. The operating model, which the company will begin implementing in the first quarter of fiscal year 2023, is designed to increase efficiency as well as move decision-making closer to consumers and customers in order to better anticipate and meet their needs. The new operating model is expected to generate ongoing annual savings of approximately $75 million to $100 million, with benefits beginning in fiscal year 2023. The company expects selling and administrative expenses to be approximately 13% of sales over time as a result of the changes and its ongoing productivity efforts. It also expects to take a charge in connection with the new operating model of approximately $75 million to $100 million over fiscal years 2023 and 2024, with approximately $35 million, or about 20 cents, to be recognized in fiscal year 2023, mostly in other income and expense.

16:13 EDT Lucid Group revises 2022 production volume outlook to 6,000-7,000 vehicles - "Our revised production guidance reflects the extraordinary supply chain and logistics challenges we encountered," said Peter Rawlinson, Lucid's CEO and CTO. "We've identified the primary bottlenecks, and we are taking appropriate measures - bringing our logistics operations in-house, adding key hires to the executive team, and restructuring our logistics and manufacturing organization. We continue to see strong demand for our vehicles, with over 37,000 customer reservations, and I remain confident that we shall overcome these near-term challenges."

16:11 EDT Lucid Group names Steven David as SVP of operations - Lucid Group announced the appointment of Steven David as Senior Vice President of Operations, reporting directly to Peter Rawlinson, Lucid's CEO and CTO. In this newly created role, Steven will lead operations encompassing supply chain, logistics, manufacturing, and quality.

16:06 EDT Syros Pharmaceuticals gets positive opinion on Tamibarotene orphan designation - Syros Pharmaceuticals announced that the European Medicines Agency (EMA) issued a positive opinion on the Company's application for orphan drug designation for tamibarotene for the treatment of myelodysplastic syndrome (MDS). Tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RARalpha) agonist, is currently being evaluated in combination with azacitidine in the SELECT-MDS-1 Phase 3 trial for RARA-positive patients with newly diagnosed higher-risk MDS (HR-MDS). Previously, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to tamibarotene in MDS in February 2022.

16:03 EDT U.S. Xpress focused on continued fleet growth in Q3 - Fuller commented, "Looking ahead to the third quarter, we are focused on continued overall fleet growth, restoring Variant's utilization to its previous levels which we believe will drive improvement in Variant's other key metrics as well as a continued focus on cost discipline and allocating capital to projects which we believe will drive the business forward. Our focused efforts in these areas are key to demonstrating the operating leverage potential of our model."

16:02 EDT Origin Materials backs FY22 adjusted EBITDA loss of up to $36M - Backs FY22 capital spending view up to $175M.

15:53 EDT Avangrid announces agreement to operate Vineyard Wind 1 project - Avangrid announced that it has finalized an agreement to assume responsibility as the operations and management services provider for Vineyard Wind 1, which it calls "the first commercial-scale offshore wind project in the United States." Vineyard Wind 1, an 800-megawatt offshore wind project owned in a 50-50 Joint Venture between Avangrid and Copenhagen Infrastructure Partners funds CI II and CI III., is currently under construction off the coast of Massachusetts. The agreements include the Operations and Maintenance Service Agreement and Asset Management Agreement, which designate Avangrid as the party responsible for overseeing the operation and management of the facility once construction is complete and commercial operations begin. "Avangrid is proud to pioneer the offshore wind industry in the United States, and by leveraging the global experience of the IBERDROLA group and a skilled and talented local workforce, we are well positioned to maximize the operation and performance of the historic, nation-leading Vineyard Wind 1 project. Offshore wind represents a tremendous opportunity to advance the United States' ambitious climate goals, and the completion and successful operation of Vineyard Wind 1 will lay the groundwork for the continued growth of the industry in the decades to come, including Avangrid's robust 4.9 Gigawatt project pipeline," said Pedro Azagra, CEO of Avangrid.

15:36 EDT General Dynamics senior VP Gallopoulos sells over 11,000 common shares - In a regulatory filing, General Dynamics senior VP Gregory Gallopoulos disclosed the sale of 11,126 common shares of the company on August 1 at a price of $227.68 per share.

15:28 EDT Enveric Biosciences trading halted, volatility trading pause

13:57 EDT North American rail traffic increased 0.6% for the week ending July 30 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending July 30, as well as volumes for July 2022. U.S. railroads originated 906,903 carloads in July , up 0.2%, or 2,213 carloads, from July 2021. U.S. railroads also originated 1,033,906 containers and trailers in July, down 3%, or 32,094 units, from the same month last year. Combined U.S. carload and intermodal originations in July were 1,940,809, down 1.5% or 29,881 carloads and intermodal units from July 2021. In July,10 of the 20 carload commodity categories tracked by the AAR each month saw carload gains compared with July 2021.These included: coal, up 5,588 carloads or 2.2%; crushed stone, sand & gravel, up 5,197 carloads or 6.7%; and motor vehicles & parts, up 3,726 carloads or 8.2%. Commodities that saw declines in July 2022 from July 2021 included: primary metal products, down 7,065 carloads or 19.2%; all other carloads, down 3,311 carloads or 15.1% and stone, clay & glass products, down 2,202 carloads or 6.7%. "Rail traffic in July was evenly balanced between commodities with carload gains and those with carload declines," said AAR Senior Vice President John T. Gray. "As such, it does not provide definitive evidence regarding the state of the overall economy. In that respect, it is very similar to most other recent economic indicators." North American rail volume for the week ending July 30, on 12 reporting U.S., Canadian and Mexican railroads totaled 333,060 carloads, up 1.9% compared with the same week last year, and 358,418 intermodal units, down 0.6% compared with last year. Total combined weekly rail traffic in North America was 691,478 carloads and intermodal units, up 0.6%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC) ,Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:52 EDT Italian Air Force extends Performance Based Logistics relationship with Boeing - Boeing and the Directorate for Air Armaments and Airworthiness, or DAAA, have signed an order for the company to continue providing full Performance Based Logistics support to the Italian Air Force four KC-767A tankers through December 2025. Under the contract, Boeing will deliver "tip to tail" support for the four ItAF refueling tankers, including line and heavy maintenance, repair, and overhaul, supply chain, engineering support, publications revisions, and flight and maintenance training.

13:48 EDT Montauk Renewables Inc trading halted, volatility trading pause

13:19 EDT Occidental says Permian CapEx hike to be mitigated by other assets - Says will pay $1.2B in U.S. taxes if WTI averages $100 per barrel in 2022.

12:47 EDT Golden Sun Education Group Ltd trading resumes

12:16 EDT Occidental Petroleum backs FY22 oil & gas production view 1,140-1,170 Mboed - Sees FY22 domestic rax rate 22%. Sees FY22 international tax rate 45%.

12:07 EDT Paramount+ to launch as a Premium Subscription within Roku Channel - Roku (ROKU) announced that Paramount+ (PARA) will launch as a Premium Subscription within The Roku Channel later this month. The launch will make Paramount+'s critically acclaimed originals, hit movies, a world class library of popular series, 24/7 news and marquee sports, accessible directly to consumers within The Roku Channel. Users can subscribe to Paramount+'s ad-supported Essential Plan or the Paramount+ ad-free Premium Plan on The Roku Channel.

12:02 EDT AMTD Digital falls -16.6% - AMTD Digital is down -16.6%, or -$279.00 to $1400.00.

12:00 EDT Clearwater Paper rises 24.1% - Clearwater Paper is up 24.1%, or $8.37 to $43.17.

12:00 EDT Ping Identity rises 59.9% - Ping Identity is up 59.9%, or $10.47 to $27.94.

11:34 EDT Voyager presents data on antibodies targeting hyperphosphorylated forms of tau - Voyager Therapeutics presented data showing the use of novel antibodies targeting hyperphosphorylated forms of tau. Two therapeutic approaches were used to show that the spread of pathological tau can be impeded in rodent models: passive immunotherapy with novel antibodies and an intravenously delivered vectorized novel antibody using a blood-brain-barrier penetrating AAV capsid. The data were presented at the Alzheimer's Association International Conference. Tauopathies such as Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia are characterized by the progressive accumulation and/or propagation of neurofibrillary tangles associated with tau hyperphosphorylation in the brains of patients, leading to neuronal and synaptic loss, brain atrophy, and inflammation. Although current therapies are limited to symptom management and have a modest impact, investigational therapeutics designed to disrupt the propagation of tau pathology may hold promise in the treatment of tauopathies. Passive Antibody Research Highlights: 113 anti-tau antibodies were characterized based on specified biochemical and biophysical properties, including functional inhibition of filamentous tau seeding in vitro and high affinity and specificity for pathological forms of tau, and antibodies that met the desired target profile were selected for in vivo efficacy screening. Four novel antibodies targeting epitopes of the mid- and C-terminus tau domains were selected. Selected antibodies were demonstrated to block the seeding/propagation of filamentous tau in a P301S seeding-propagation tauopathy mouse model and demonstrated substantial reduction of induced tau pathology. Vectorized Antibody Research Highlights: Vectorized antibody expression was detected in the hippocampus, cortex, and cerebrospinal fluid of mice as soon as two days after administration with sustained durability of expression more than six months post-dose. The vectorized antibody was observed to be well tolerated at all assessed doses, with robust efficacy observed in all P301S hippocampal seeding/propagation and P301S intrinsic mouse models of tauopathy. These results build upon previous findings demonstrating distribution and expression of vectorized anti-tau antibodies in the mouse brain using a blood-brain barrier penetrant capsid administered intravenously.

11:31 EDT Athira Pharma presents data from ACT-AD Phase 2 proof-of-concept study - Athira Pharma announced that Hans Moebius, M.D., Ph.D., Athira's Chief Medical Officer, is leading an oral presentation titled, "ACT-AD: Fosgonimeton in Mild-to-Moderate Alzheimer's Disease - First Results of a Randomized, Placebo-Controlled, 26-Week Phase 2 Proof-of-Concept Trial" today at the Alzheimer's Association International Conference, or AAIC. As previously reported, the ACT-AD study did not meet the primary endpoint of a statistically significant change in ERP P300 Latency for the modified intent to treat population by a mixed model repeated measures analysis when compared with placebo at 26 weeks in a pooled analysis of the 40 mg and 70 mg dose groups. Secondary endpoints, including ADAS-Cog11, ADCS-CGIC, and ADCS-ADL23, were not statistically significant in treated subjects compared with placebo at 26 weeks as the study was only powered to show statistical significance for change in ERP P300 latency. Dr. Moebius said: "While the primary outcome analysis did not reach statistical significance, these data have given us meaningful insights into fosgonimeton's potential effects. Importantly, they showed fosgonimeton's potential activity, including a reduction in plasma levels of the fluid biomarker, neurofilament light chain, a validated biomarker of neurodegeneration, in this mild-to-moderate Alzheimer's disease patient population and demonstrated its favorable tolerability and safety profile over six months. We were particularly pleased to detect numerical improvements in ADCS-ADL23, a functional measure of activities of daily living and a secondary endpoint in ACT-AD. Independence and function are critically important to patients and caregivers, impacting quality of life, caregiver burden and healthcare costs. Current treatment options have limited effect on this measure, and we believe that, if borne out in further clinical trials, fosgonimeton may potentially lead to functional improvement in patients suffering with Alzheimer's disease. In addition, we detected a statistically significant improvement in NfL plasma concentration in a pre-specified subgroup analysis of subjects treated with fosgonimeton monotherapy compared with placebo, and a numerical improvement was shown in all fosgonimeton treated patients. Overall, these findings are congruent with the previously reported numerical improvements in ERP P300 latency and ADAS-Cog11 in subjects treated with fosgonimeton monotherapy and suggest that fosgonimeton may have potential benefit for Alzheimer's patients."

11:05 EDT Insperity adds Jim Furyk to Brand Ambassador Program - Insperity announced the expansion of its Brand Ambassador Program with the addition of Jim Furyk, one of the PGA TOUR's most recognized and talented golfers, as well as talented up-and-coming golfers Cole Hammer, Mac Meissner and Karen Fredgaard.

11:02 EDT Keysight, Nokia collaborate on public 800GE test - Keysight Technologies (KEYS) announced it has collaborated with Nokia (NOK) to demonstrate the first public 800GE test, validating the readiness of next-generation optics for service providers and network operators. With the move to the 800GE pluggable optics on front panel ports, interconnect and link reliability requires a new round of validation cycles to support carrier-class environments. These high-speed interfaces create a unique challenge as new 800GE capable silicon devices, optical transceivers and high bandwidth Ethernet speeds must be accurately tested. The readiness testing was conducted at Nokia's private SReXperts customer event in Madrid in June 2022, and included Keysight's AresONE 800GE Layer 1-3 800GE line rate test platform and the Nokia 7750 Service Routing platform. The AresONE was used to test and qualify Nokia's FP5 network processor silicon along with 800GE pluggable optics. Specific Nokia platforms used in the validation were the FP5 based 7750 SR-1x-48D supporting 48 ports of 800GE and the 7750 SR-1se supporting 36 ports of 800GE.

10:37 EDT Ampio to lay off 10 of 18 employees, stop development of Ampion - Ampio Pharmaceuticals says it committed to a reduction in force that will result in the termination by August 31 of 10 of its current 18 employees, or approximately 55.5%. The company's decision to engage in this reduction results from the board's determination not to pursue the continued development of Ampion as part of its review of strategic alternatives. At this time, the company is discontinuing development of Ampion for all indications and discontinuing most other development activities pending conclusion of the strategic alternatives process. "The reduction in force is a measure to manage costs and conserve cash resources with the goal of maximizing the opportunities available to Ampio during the Board's review of strategic alternatives," it said. Ampio expects to record a charge of up to $425,000 in Q3 relating to the reduction in force for the employees being terminated by August 31. It also expects to record a charge of up to $355,000 beginning in Q3 and continuing through Q4 relating to the retention and severance arrangements.

10:36 EDT Ampio says executives did not fully report results of AP-013 trial - Ampio Pharmaceuticals said in a letter to shareholders, "As it relates to the AP-013 clinical trial, the Special Committee's primary findings include that certain former Ampio executive officers and senior staff were aware, at the time of the per-protocol interim analysis in March 2020, that the AP-013 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function; and that these former Ampio executive officers and senior staff did not fully report the results of the AP-013 trial and the timing of unblinding of data from the AP-013 trial. The Special Committee has determined that the Company's current executive officers were not made aware of the unblinding events in March 2020. Through counsel, the Company and the Special Committee have informed the Securities and Exchange Commission of the investigations. The Company and the Special Committee also have contacted the FDA regarding this investigation...With this context in mind, we have been pursuing other strategic alternatives for Ampio with the goal of maximizing value for Ampio stockholders. This exercise includes the potential for Ampio to acquire a product/pipeline and/or execute a reverse merger with a company that is seeking an NYSE American listing and has a development candidate and/or pipeline that we believe would represent a better value proposition for Ampio stockholders." With the assistance of a financial advisor, we have identified several potential acquisition and reverse merger candidates, as well as received inbound interest from potential counterparties for several transformative transactions. We are diligently evaluating all opportunities in terms of value returned to the Ampio stockholders, but this selection process takes time.

10:01 EDT Hill International selected by TMG for project management services - Hill International announced that it was selected by the Talaat Moustafa Group to provide project management, construction management, and site supervision services for the Four Seasons Hotel Luxor, Egypt. Sited on the Nile River, the hotel and its annexes will be located on 21,400 SM of land in Sultana Malak in the Luxor Governorate. The five-star, premium tourist hotel will comprise around 200 rooms and suites, restaurants, meeting rooms, parties, gymnasiums, a health club, and other annexes. The project's anticipated completion date is March 2025. Waleed Abdel-Fatah, Senior Vice President of Hill's Africa region said of the selection: "The Hill team has been a proud member of numerous projects in Egypt's cultural and tourism industries, including several assignments for TMG. We understand the importance of these projects in promoting the nation as a unique, high-end destination. TMG's new Four Seasons project marks Hill's entrance into the booming Luxor tourism sector and is sure to be a new gem for the area."

10:00 EDT Daily S&P Biotech Bear 3x Shares falls -12.8% - Daily S&P Biotech Bear 3x Shares is down -12.8%, or -$3.49 to $23.77.

10:00 EDT Clearwater Paper rises 29.2% - Clearwater Paper is up 29.2%, or $10.16 to $44.96.

10:00 EDT Ping Identity rises 59.5% - Ping Identity is up 59.5%, or $10.39 to $27.86.

09:57 EDT Scotts Miracle-Gro doesn't expect 'drastic deviation' in FY23 EPS vs. FY22 - The company said it doesn't expect a significant decline or significant growth in FY23 EPS vs. FY22. FY23 EPS consensus is $6.11. Comments taken from Q3 earnings conference call.

09:47 EDT MyMD Pharmaceuticals MYMD-1 study shows significant improvements in lifespan - MyMD Pharmaceuticals announced the publication of data in the Journal of Gerontology: Biological Sciences from a pre-clinical study of MYMD-1 demonstrating four-fold greater improvements than rapamycin in delaying aging and extending the life of mice who began treatment at the human equivalent of 60 years of age. The study was led by principal study investigator Patrizio P. Caturegli, MD, MPH, a professor of pathology at the Johns Hopkins University School of Medicine. A Phase 2 multi-center double-blind, placebo controlled, randomized study to investigate the efficacy, tolerability and pharmacokinetics of MYMD-1 in the treatment of chronic inflammation associated with sarcopenia/frailty is currently ongoing. The company's scientific advisory board met recently and agreed to move to the next higher dose in the study. The study compared MYMD-1, an oral inhibitor of TNF-alpha, to rapamycin, the best characterized drug endowed with anti-aging properties. In vivo, a longitudinal cohort of C57BL/6 mice, was randomized to receive either MYMD-1, high-dose rapamycin, or low-dose rapamycin plus metformin. Each of these three treatment arms of 18 mice was followed for 13 months or until death. Lifespan was significantly longer in the MYMD-1 group compared to rapamycin in a Cox survival model that accounted for sex and serum levels of IL-6, TNF-alpha, and IL-17A. MyMD-1 also improved several health span characteristics in the study, resulting in milder body weight loss, maintenance of greater muscle strength, and amelioration of progression to frailty.

09:47 EDT Southwest Gas falls -12.3% - Southwest Gas is down -12.3%, or -$10.77 to $76.55.

09:47 EDT AMTD Digital rises 20.8% - AMTD Digital is up 20.8%, or $350.00 to $2029.00.

09:47 EDT Ping Identity rises 59.9% - Ping Identity is up 59.9%, or $10.46 to $27.93.

09:43 EDT AMTD Digital Inc trading resumes

09:28 EDT Tejon Ranch to continue to invest in residential properties - The Company will continue to aggressively pursue commercial/industrial development, multi-family development, leasing, sales, and investment within TRCC and its joint ventures. The Company will continue to invest in its residential projects, including Mountain Village at Tejon Ranch, Centennial at Tejon Ranch and Grapevine at Tejon Ranch. California is one of the most highly regulated states in which to engage in real estate development and, as such, natural delays, including those resulting from litigation, can be reasonably anticipated. Accordingly, throughout the next few years, the Company expects net income to fluctuate from year-to-year based on commodity prices, production within its farming segment and mineral resources segment, and the timing of sales of land and the leasing of land within its industrial developments.

09:23 EDT Cassava Sciences expects results from CMS study of simufilam in 3Q23 - In May 2021, we initiated a Cognition Maintenance Study. This is a double-blind, randomized, placebo-controlled study of simufilam in patients with mild-to-moderate Alzheimer's disease. Study participants are randomized to simufilam or placebo for six months. The CMS is designed to evaluate simufilam's effects on cognition and health outcomes in Alzheimer's patients who continue with drug treatment versus patients who discontinue drug treatment. To enroll in the CMS, patients must have previously completed 12 months or more of open-label treatment with simufilam. The target enrollment for the CMS is 100 or more patients. Over 50 patients have now completed this study. Our goal is to complete patient enrollment for the CMS in Q4 2022. We expect to announce clinical results of the CMS approximately third-quarter 2023.

09:21 EDT Cassava expects topline results for open-label study of simufilam year-end - In March 2020, we initiated a long-term, open-label study to evaluate simufilam in patients with mild-to-moderate Alzheimer's disease. The study is intended to monitor the long-term safety and tolerability of simufilam 100 mg twice daily over 12 months or more. This study has reached its target enrollment of approximately 200 patients. We expect all patients for this study will complete drug treatment in Q4 2022. We expect to announce top-line clinical results for this study approximately year-end 2022.

09:19 EDT Cassava Sciences says over 400 patients enrolled in Phase 3 program of simufilam - A total of over 400 patients are now enrolled in our on-going Phase 3 program of simufilam in Alzheimer's disease. Enrollment is almost evenly split between the two Phase 3 studies.

09:18 EDT Imax and Cineworld expand partnership to 52 Imax locations by 2026 - IMAX and Cineworld announced an expansion of their partnership, under which 52 IMAX locations across Cineworld's worldwide footprint will be upgraded or opened by 2026. Cineworld and IMAX had previously contracted for 47 new or upgraded IMAX systems and under the new agreement will add an additional five new IMAX with Laser systems across the UK and Europe. Under the agreement, Cineworld Leicester Square in London, Regal Irvine Spectrum in California, and Regal UA Sheepshead Bay in New York City will all feature IMAX with Laser. Cineworld currently operates the most IMAX locations in Europe. IMAX with Laser features a 4K laser projection system that features a new optical engine, custom designed lenses, and a suite of proprietary technology.

09:17 EDT Lear commits to 100% renewable electricity for its global sites by 2030 - Lear announced it has joined Climate Group's RE100, a global renewable electricity initiative that includes over 370 major companies. RE100 members commit to sourcing 100% of the electricity used across their global operations with electricity produced from renewable sources. By integrating its Energy Efficiency Playbook and renewable energy strategy across the company, Lear plans to achieve 100% renewable energy for electric power consumed at its global sites by 2030. Lear's operations in Germany, Poland and the United Kingdom currently meet the goal. In addition, the company is operating six on-site solar installations in Europe, South America, and Asia, with a seventh installation planned to be announced later this year.

09:16 EDT Silicom receives $3M product order from a US-based provider of SASE solutions - Silicom announced that it has secured an initial ~$3M order from a US-based provider of cloud-based SASE solutions. This fast-growing client will use Silicom's Edge platforms with minor customizations to provide both wired and wireless connectivity to its end-customers. While the customer requested immediate delivery of the full order, the actual delivery schedule will be extended over the next quarters due to global shortages in needed components.

09:15 EDT Fortune Brands executes extension of current $1.25B facility to Aug 2027 - Fortune Brands Home & Security announced that on Aug. 2 the Company executed an extension of its existing five-year revolving credit agreement. The new agreement extends the Company's current $1.25B Senior Unsecured Revolving Credit Facility for a five-year term, dated for maturity on Aug. 2, 2027. The proceeds from the agreement will be used for general corporate purposes, and the agreement will continue as a part of the Company's capital structure post separation of the Cabinet business.

09:11 EDT Connexa Sports appoints Gabriel Goldman to board of directors - Connexa Sports Technologies announced the appointment of Gabriel Goldman to its Board of Directors. Mr. Goldman is the second appointment to the Board following along the announcement of Rohit Krishnan last month. Goldman has been serving on the Board of Directors since June 15th. He founded Pileus, which was acquired by Anodot, and previous to that was a Senior Engineer with Intuit

09:09 EDT Ansys sets 2027 carbon reduction target of 15% - Ansys plans to reduce the environmental and climate impacts of its operations by measuring, analyzing, and reducing resource use. The simulation software provider's goal is to reduce scope 1 and scope 2 emissions by 15% by 2027, compared with its current 2019 baseline. The company also extends its commitment through simulation solutions that help users minimize materials waste, improve circularity, accelerate product development processes, and minimize physical prototyping.

09:08 EDT Under Armour sees 'overabundance' of product hitting the market in 2022

09:06 EDT O'Reilly Automotive sees strong sales, company growth with early 2022 momentum - O'Reilly announced 1H 2022 momentum results detailing a period of explosive growth for the company. Driven by market demand for learning and training technology to help solve the skills gap challenge, O'Reilly saw a 45% growth in sales for new enterprise bookings year-over-year, along with more than 80 new hires, new additions to its executive team, new banner clients, awards, accolades, and more. "In 2020, O'Reilly adopted a remote-first culture, giving employees the ability to work wherever they were most productive and opening access to a global pool of talent. As a result, we've been able to expand into new regions, welcome new banner customers, and hit high enterprise sales growth, all within the first half of 2022," said Laura Baldwin, president of O'Reilly. "We've continued to focus on delivering the highest quality technical content to our customers-a core reason we're seeing such strong growth. Over the last year, we've continued to focus on innovative new ways to deliver that content and learning through our platform."

09:05 EDT MSC Industrial acquires Tower Fasteners - MSC Industrial has acquired Tower Fasteners, a Holtsville, New York-based distributor of Original Equipment Manufacturer fasteners and components. Tower will continue to operate under its current name after becoming an MSC company. Mark Shannon, President of Tower, will continue to lead the business, which has approximately 100 associates. Tower's revenue in calendar 2021 was approximately $35M. Tower operates eight distribution centers along the East Coast and in the Southwestern regions of the United States, Mexico and Europe. Tower serves manufacturers in the industrial, electronics, medical equipment, aerospace, military, and security, fire and safety sectors. MSC plans to maintain Tower's operations. The acquisition is expected to be roughly neutral to MSC's FY22 earnings and slightly accretive to FY23 earnings.

09:04 EDT Amylyx announce FDA advisory committee will reconvene to review NDA for AMX0035 - Amylyx Pharmaceuticals announced that the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee, PCNSDAC, will reconvene to review the New Drug Application, NDA, for AMX0035 for the treatment of amyotrophic lateral sclerosis, ALS. The second virtual meeting of the PCNSDAC to discuss the AMX0035 NDA is scheduled, as published in the Federal Register, for September 7, 2022. The PCNSDAC previously met on March 30, 2022, to discuss the NDA for AMX0035 for the treatment of ALS. The FDA is reconvening the committee to discuss the additional analyses of data from the Company's clinical studies that were determined by the FDA to constitute a major amendment to the NDA. As a result, FDA extended the Prescription Drug User Fee Act target action date for the AMX0035 NDA to September 29, 2022, from the original date of June 29, 2022. "We are determined to do everything we can to bring AMX0035 to people living with ALS, and we look forward to another robust scientific discussion with the members of the advisory panel regarding the additional analyses from our clinical studies and the potential of AMX0035," said Jamie Timmons, M.D., Head of Scientific Communications of Amylyx. "We remain confident in the data, including the recently published analyses supporting the previously reported functional and overall survival benefit for AMX0035. There is an urgent unmet need for new and effective treatments in ALS, and our team is working nonstop to continue our mission to end the suffering caused by neurodegenerative diseases."

09:03 EDT Riot Blockchain produces 318 bitcoin in July - Riot Blockchain announces unaudited production and operations updates for July 2022. Bitcoin Production and Operations Updates: In July 2022, Riot produced 318 BTC, a decrease of approximately 28% as compared to July 2021 production of 443 BTC, while significantly reducing overall power costs through effective employment of its proprietary power strategy. Riot earned an estimated $9.5 million in power credits as a result of curtailment activity, to be credited against its power invoices; the $9.5 million in power credits equates to approximately 439 BTC, computed by using the July 2022 average BTC price of $21,634. As of July 31, 2022, Riot held approximately 6,696 BTC, all produced by the Company's self-mining operations. In July 2022, Riot sold 275 BTC, generating net proceeds of approximately $5.6 million. Riot currently has a deployed fleet of 40,311 miners, with a hash rate capacity of 4.2 exahash per second. Current hash rate capacity has been temporarily impacted by the ongoing relocation of a portion of the Company's mining fleet, from a third-party hosting facility to Riot's Whinstone Facility, which is ultimately expected to further reduce production costs. Riot's Q2 2022 financial report is planned to be released after market close Tuesday, August 9, 2022. "We are pleased to report that Riot has demonstrated the effectiveness of its power strategy during the month of July. The Company has consistently and proactively pursued low-cost, large-scale access to power under its long-term fixed rate power contracts, providing it with a unique ability to support ERCOT and release capacity back into the grid when power demand in Texas is high," said Jason Les, CEO of Riot. "As energy demand in ERCOT reached all-time highs this past month, the Company voluntarily curtailed its energy consumption in order to ensure that more power would be available in Texas. Riot curtailed a total of 11,717 megawatt hours in July, enough to power 13,121 average homes for one month. Curtailing the Company's power consumption reduced BTC production by an estimated 21% in July, but also significantly reduced Riot's power costs for the month. By providing power back into the ERCOT grid during periods of peak demand, the Company estimates that power credits and other benefits from curtailment activities totaled an estimated $9.5 million, significantly outweighing the reduction in BTC mined. When applied to anticipated power costs for the month, the power credits and other benefits are expected to effectively eliminate Riot's power costs for July, further enhancing the Company's industry-leading financial strength amid a challenging macroeconomic environment for the industry."

09:02 EDT Xerox appoints Bandrowczak as Chief Executive Officer - Xerox announced its Board of Directors has appointed Steven Bandrowczak as Chief Executive Officer. Steve joined Xerox in 2018 as the company's President and Chief Operations Officer, and has served as Interim CEO since the passing of John Visentin in June 2022. As President and COO, Steve was responsible for developing and executing a global operations strategy for Xerox's Software and Innovation businesses, as well as the company's business support functions, including business strategy, product and service delivery, customer billing, and information technology.

09:02 EDT Fox Corp., Verizon announce new multi-year distribution agreement - Fox Corporation (FOXA, FOX) announced the completion of a multi-year renewal of its distribution agreement with Verizon (VZ) for its Fios TV platform. The agreement includes the continued distribution of the full portfolio of FOX brands including FOX News Media, FOX Sports, FOX Network and local FOX O&O TV stations in markets including New York, Washington, D.C. and Philadelphia. FOX Weather will also be added to the Fios TV lineup, and Tubi will be included in both Fios TV set top boxes, as well as on many other platforms.

08:46 EDT NeoVolta adds $555,700 in purchase orders - NeoVolta announced purchases by PMP Energy over the past two months valued at $555,700. These purchase orders are part of a three-year exclusive distribution agreement signed by the two companies in 2019. Under the agreement, PMP Energy provides dealers with training and certification to install NeoVolta energy storage systems in homes and other locations.

08:41 EDT Verizon Connect unveils AI Dashcam - To provide fleet managers with a greater range of insight into dangerous events and in-cab coaching to alert drivers in real time of high risk driving behaviors, Verizon Connect is unveiling its advanced Artificial Intelligence Dashcam. The new Verizon Connect Dashcam utilizes advanced AI to enable real-time detection of potentially dangerous driving events and to boost driver safety. Available for new and existing Fleet and Reveal customers, Integrated Video is available for use with two new camera models, including a road-facing only camera - which can be upgraded with a driver-facing camera add-on - and a dual-facing camera.

08:40 EDT Under Armour's Plank: Interim CEO Colin Browne has done 'outstanding' job

08:39 EDT Under Armour focused on search for permanent CEO, says Plank

08:37 EDT Under Armour sees selecting permanent CEO by end of year - Comments taken from Q1 earnings conference call.

08:37 EDT nCino announces executive leadership appointments - nCino announced several new appointments across its executive leadership team to further support the Company's continued growth, scale and product innovation. The following changes across nCino's executive leadership team are effective immediately: Matt Hansen has been named Chief Product Officer of nCino, overseeing the Company's Product Development & Engineering organization globally. In 2011, Hansen founded SimpleNexus, an nCino company, and served as its Chief Executive Officer for more than 10 years. Jaime Punishill has been named Chief Market Officer of nCino, taking over for Jonathan Rowe, Ph.D., who is taking on a new strategic role with the Company after serving as its CMO since 2012. Punishill joins nCino from Lionbridge, a leading translation and localization company, where he has served as their Chief Marketing Officer for the past five years. Ben Miller has been named Chief Executive Officer of SimpleNexus, an nCino Company, taking over for Cathleen Schreiner Gates, who will remain with the Company in an advisory capacity. Miller co-founded SimpleNexus and has played a critical role in scaling the business into the leading digital homeownership software company in the U.S.

08:34 EDT Cornerstone announces completion of Phase 1b trial of CPI-613 - Cornerstone Pharmaceuticals announced the successful completion of a Phase 1b clinical trial of CPI-613 in combination with gemcitabine and cisplatin for the treatment of advanced unresectable biliary tract cancer. In collaboration with Michigan Medicine, the Phase 1b study consisted of a multicenter trial of gemcitabine and cisplatin with devimistat as first-line therapy for patients with locally advanced unresectable or metastatic biliary tract cancer. The Phase 1b portion of the trial enrolled 20 patients and concluded that the combination of gemcitabine and cisplatin with devimistat is well tolerated. The trial reported encouraging data with an overall response rate of 45% and a median progression-free survival of 14.9 months with seven patients still in treatment. After a median follow-up of 11.5 months, the overall survival is not yet estimable. The randomized Phase 2 portion of the trial is open and accruing patients across 10 cancer centers in the U.S., targeting an enrollment of 78 patients.

08:33 EDT Nuvista Energy sees 2022 production 67,000-69,000 boe/d

08:33 EDT Nuvista Energy sees Q3 production 67,000-69,000 boe/d - As discussed above, NuVista is pleased to note that operations and performance have been strong while both condensate and natural gas prices have continued at highly profitable levels. This results in a material increase to projected adjusted funds flow, tremendous progress in reducing our net debt, and high velocity of capital investment return. Capital spending and inflationary assumptions have been on track to prior estimates thus far. NuVista's capital expenditure guidance for 2022 is re-affirmed at a range of $355 - $375 million. We will revisit this in the fall to assess any changes to inflationary pressures. Additionally, if commodity pricing and production continue to perform well, we will review the optionality of moving some planned activities from the first quarter of 2023 to the fourth quarter of 2022 to again optimize supply chain management and execution outcomes. NuVista's recent well performance has been strong, and all planned outages for the year have been concluded. We have set our third quarter production guidance range at 67,000 to 69,000 Boe/d. Full year 2022 guidance is reaffirmed at 67,000 - 69,000 Boe/d.

08:31 EDT IntercontinentalExchange reports July total ADV up 3% y/y - July highlights include: Total average daily volume up 3% y/y and total open interest up 3% y/y. Total natural gas ADV up 14% y/y; OI up 7% y/y; North American natural gas ADV up 25% y/y; OI up 14% y/y; Sugar ADV up 15% y/y; Cocoa ADV up 11% y/y; OI up 24% y/y; Cotton ADV up 37% y/y; OI up 8% y/y; Total Financials ADV up 17% y/y; OI up 13% y/y.

08:26 EDT BASF enters VPPAs for clean energy supply of more than 20 BASF sites - BASF has entered into virtual power purchase agreements, VPPAs, for wind and solar power totaling 250 megawatts, MW. They are designed to offset the carbon-intensive grid-supplied electricity being used at more than 20 of BASF's manufacturing sites in several states across the country, from Texas to Michigan. "Renewable energy is an essential tool to reach BASF's ambitious goal of net zero emissions by 2050," said Michael Heinz, Member of the Board of Executive Directors, BASF SE and Chairman and CEO of BASF Corporation. "We are committed to further improving our energy footprint in the region and we are eager to drive the energy transition for chemical manufacturing in North America." The combined agreements for the output of 250 MW of renewable generation capacity will result in the purchase of more than 660,000 megawatt hours of electricity per year - the equivalent of electricity consumed by more than 90,000 average U.S. households. Based on EPA estimates, the VPPAs will offset more than 472,500 metric tons of CO2 emissions annually.

08:23 EDT Asure Software announces Asure Tax Portal - Asure Software announced its new Asure Tax Portal which provides clients with unprecedented transparency into their tax returns, schedule, agency status, tax funding, and payment status-from a single web portal. The Asure Tax Portal also enables accountants and third-party payroll providers to save time, better serve their clients, and make tax compliance easier.

08:20 EDT Enlivex Therapeutics receives notice of allowance for US patent on Allocetr - Enlivex Therapeutics announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for patent application number 16/594,463. Once issued, the resulting patent will provide Enlivex with added intellectual property protection into at least 2036 with additional claims covering methods of treating sepsis with Allocetr, on top of previously granted patents. The Company expects that this new patent will be issued in the United States in the fourth quarter of 2022. "Receiving this Notice of Allowance is an important corporate achievement that we believe positions us to optimize Allocetra's commercial potential in sepsis," said Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex. "The resulting patent will provide an additional layer of protection for this program, which targets a multi-billion-dollar market that is not well served by current therapies. In addition, we continue to work diligently to further expand our IP portfolio with patents covering Allocetra's(TM) use in other indications." Interim results from the trial are expected in the first quarter of 2023. Top-line data are expected in the third quarter of 2023.

08:19 EDT MeiraGTx announces financing agreement up to $100M - MeiraGTx Holdings announced a term loan agreement with affiliates of Perceptive Advisors for up to $100 million, including $75 million upon closing. Under the term loan agreement, the Company received $75 million upon closing and may request an additional $25 million during the first two years of the term under the same terms and collateral, subject to the lender's approval. The credit facility is interest-only for 4 years, with a maturity date of August 2, 2026, when the principal will be due. The interest rate is 10% plus the greater of 1% or one-month CME Term SOFR. In connection with the closing, the Company issued Perceptive warrants exercisable into 400,000 ordinary shares of the Company with a per share exercise price of $15.00 and additional warrants exercisable into 300,000 ordinary shares of the Company with a per share exercise price of $20.00. MeiraGTx intends to use the proceeds for the continued development of its clinical-stage product candidates, preclinical programs and technology platforms, and for other general corporate purposes.

08:18 EDT BitNile provides update on Bitcoin mining operations - BitNile (NILE) published an unaudited update on Bitcoin (BTC) production and miner deliveries. BitNile's Bitcoin mining production is currently operating at an estimated annualized run rate of 719 Bitcoin based on current market conditions, including a mining difficulty of 27.69 trillion. BitNile has increased its miner count to 11,949 S19j Pro Antminers in its possession and once installed will generate a combined processing power of approximately 1.19 exahashes per second, the computational power that is being used to mine Bitcoin. During the month of July 2022, BitNile self-mined 59.9 Bitcoin. To date, BitNile has mined a total of 316.4 Bitcoin. As of July 31, 2022, BitNile held approximately 200 Bitcoin and currently has no plans to sell. BitNile expects to receive 20,600 miners by the end of 2022. Once fully deployed and operational, BitNile is expected to achieve mining production capacity of approximately 2.24 exahashes per second.

08:17 EDT Ocuphire Pharma extends US patent protection for Nyxol - Ocuphire Pharma announced the issuance of U.S. Patent No. 11,400,077. The patent provides added intellectual property protection for the company's late-stage product candidate, Nyxol, with claims directed to methods for treating mydriasis using phentolamine mesylate. The patent is eligible for listing in the U.S. FDA Orange Book and has a term extending into year 2039. "We are very pleased with the issuance of this new patent for Nyxol, which extends our intellectual property protection in the U.S. by an additional five years into 2039," said Mina Sooch, MBA, Founder and CEO of Ocuphire Pharma. "Last year we were granted a new U.S. Patent for presbyopia extending our existing patent estate into year 2039 and now we are very pleased with the issuance of this new patent for Nyxol in reversal of mydriasis," said Mina Sooch, MBA, President and CEO of Ocuphire Pharma. "As we own the worldwide rights to Nyxol for all indications, this added protection will position us to maximize the commercial value of Nyxol for at least 15 years in reversal of mydriasis as we plan to submit an NDA to the FDA later this year. If approved, Nyxol could be launched in the second half of 2023."

08:16 EDT Playstudios announces launch of new blockchain division - PLAYSTUDIOS announced the launch of its new blockchain division, playBLOCKS. The company said: "playBLOCKS will extend PLAYSTUDIOS' leadership in "rewarded play'' by leveraging blockchain technologies and economic models that will: deliver more engaging and rewarding experiences to players across its portfolio of games; provide new capabilities to rewards partners; and offer a more secure marketplace for both players and rewards partners to connect." PLAYSTUDIOS also announced its intention to invest in innovative companies shaping the future of rewarded play. The company refers to its plans as the "Future Fund," and has seeded it with an initial sum of $10M.

08:16 EDT Catalyst announces ISS, Glass Lewis recommend shareholders vote FOR nominees - Catalyst Biosciences announced that leading proxy advisory firms Institutional Shareholder Services, ISS, and Glass Lewis have recommended that Catalyst stockholders vote FOR all of the Company's nominees on the WHITE proxy card in advance of Catalyst's upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022. In its report, ISS specifically noted: "In light of the board's success at selling the complement portfolio for more than the market's expectations, and its commitment to make an initial cash distribution to shareholders following the resolution of the dissident's proxy contest and litigation, shareholders appear to be best served by encouraging the board to continue pursuing its existing plan." In its report, Glass Lewis specifically noted: "Given that the board has already implemented the Dissident's core suggestions for the Company, we believe there is insufficient basis to support the Dissident's campaign for further board seats at this time." On behalf of the Board, Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences, commented, "We are pleased that both ISS and Glass Lewis have recommended that Catalyst stockholders support the reelection of our three nominees. Augustine Lawlor, Dr. Geoffrey Ling and Eddie Williams are highly qualified leaders, each of whom played an important role in developing our Cash Distribution Plan and is fully committed to implementing the Plan for the benefit of all stockholders."

08:15 EDT CVS Health says posted strong results across all business segments in Q2 - Seeing "continued positive momentum" across all businesses. Says Medicare business remains one of the company's strongest growth segments. Expects to show positive membership growth in 2023. Says retail script growth is "remarkable." Says on track to close 300 stores this year. Says well-positioned to continue momentum in 2H22. Comments taken from Q2 earnings conference call.

08:14 EDT Soluna Holdings appoints Patman as CFO - Soluna (SLNH) has announced the appointment of Phil Patman Jr. as Chief Financial Officer, CFO. As CFO, Patman will spearhead finance and accounting with a specific focus on capital markets and acquisitions for Soluna and its growing pipeline of green data centers co-located with renewable power plants. Most recently, Patman served as Vice President and Head of Renewable Fuels M&A and Strategy at Ameresco (AMRC).

08:13 EDT BorgWarner installs first fast charging station in Italy - The first units of BorgWarner's new fast-charging station, Iperion-120, have been installed by the Italian service provider Route220. The Iperion-120 has the possibility of fully charging one car at 120 kW or charging two vehicles simultaneously at a maximum power of 60 kW each.

08:11 EDT Gevo, Alaska Air enter sustainable aviation fuel sales agreement - Gevo, Inc. (GEVO) announced a new fuel sales agreement with Alaska Airlines (ALK). The Agreement provides for Alaska Airlines to purchase 37 million gallons per year of sustainable aviation fuel for five years through Gevo's future commercial operations. Gevo's SAF deliveries are expected to begin in 2026.

08:08 EDT Greenwich Life actively preparing additional US sites for Flamingo-01 trial - Greenwich LifeSciences announced the following: "As previously disclosed, clinical trial contracts and budgets have been executed at multiple hospitals and the largest oncology network in the US. Clinical site initiation visits to train clinicians, nurses, coordinators, and pharmacists are underway, after which sites will be activated and the Flamingo-01 Phase III clinical trial will commence. We continue to actively recruit and prepare additional US clinical sites. The Company is continuing to make progress to initiate clinical sites in Europe through oncology networks, potentially including networks in Germany, Spain, and France. Following site activation, patients will be screened, tested for HLA type, randomized, and enrolled into any of 3 clinical trial arms, and treatment of the first patients will begin. Certain aspects of each arm will be open label, and the 3rd arm exploring HLA types that are not HLA-A02 will be entirely open label... Pharmacy process testing is nearing completion, which is anticipated to be the final testing required to commence Flamingo-01 and to start treating patients."

08:07 EDT Establishment Labs announces completion of enrollment in Motiva US IDE study - Establishment Labs Holdings announced it has completed enrollment in the Motiva US IDE clinical study. The final surgery in the primary reconstruction cohort was completed at Northwestern Memorial Hospital. The Augmentation cohort, which finished enrollment in August of 2019, will complete its third year of study follow-up this month. The Motiva US IDE study enrolled 827 patients at 32 centers in the US, Germany, and Sweden. The study is designed to assess the safety and effectiveness of Motiva breast implants in primary breast augmentation, primary breast reconstruction, and revision breast procedures. The study included 562 patients in the augmentation cohorts and 265 in the reconstructive cohorts. The study includes a Magnetic Resonance Imaging cohort of 250 patients who receive MRIs at years 1, 2, 3, 5, 7, and 10 to assess for silent rupture.

08:05 EDT Alaska Air makes significant investment in sustainable aviation fuel - Alaska Airlines (ALK) announced it has finalized an agreement with biofuel company Gevo Inc. (GEVO), to purchase its most significant sustainable aviation fuel offtake commitment to date - 185M gallons of SAF over five years starting in 2026. This agreement was developed alongside others in the oneworld alliance.

08:04 EDT Southwest Gas concludes strategic review, to continue to execute strategic plan - Southwest Gas provided an update on the company's ongoing strategic alternatives process that was initiated on April 18, stating that its board has has "unanimously determined" that the best path forward to maximize value for all stockholders is to focus on the execution of the strategic plan and conclude the strategic review process for Southwest Gas and Southwest Gas Corporation; continue to review strategic alternatives for MountainWest Pipelines Holding Company; and continue to review strategic alternatives for Centuri Group, including a sale or a spin-off of Centuri. E. Renae Conley, Chair of the Board, said: "After carefully evaluating all indications of interest, and considering Southwest Gas Corporation's strong long-term rate base growth, improving earned ROEs and favorable demographics, we believe that the best alternative to maximize the value of the utility for stockholders is to continue to execute our strategic plan at the utility. We recognize that we have a great asset and a strong opportunity to optimize the utility. Southwest Gas Corporation is well positioned with significant population growth, strong demand across its service territories and expanded services for renewable natural gas and compressed natural gas delivery. Our constructive relationships with regulators, and our collaborative approach to working with all stakeholders, will continue to position Southwest Gas Corporation for success as we meet the energy needs of our customers throughout our service territories and build upon the strong rate base capture and near record growth and revenues that we delivered in 2021. The Board also determined to advance the processes to maximize the value of Centuri and MountainWest. As such, we continue to assess the opportunity to realize the value of Centuri, one of the nation's leading utility infrastructure services providers, either via a sale or spin-off, and also a sale of MountainWest, a unique and structurally advantaged asset. We are confident that Southwest Gas Corporation is poised for growth and value creation while we continue to deliver on our safety promise, provide excellent service to our customers, create new opportunities for employees and provide energy solutions within an evolving energy landscape." Consistent with the May 6, Cooperation Agreement with Icahn Capital LP and affiliates, the Company expects Jose A. Cardenas to step down from the Board shortly, and a new director will be appointed. "Southwest Gas does not intend to make any further public comment regarding the strategic alternatives review process until it has been completed or the Company determines that a disclosure is required. Any transaction will be subject to closing contingencies and no assurances can be given regarding the outcome or timing of the alternatives process or any transaction closing. Southwest Gas will report second quarter 2022 financial results on August 9," the company said.

08:02 EDT Morphic expects cash to fund operating expenses into 2H25 - As of June 30, 2022, Morphic had cash, cash equivalents and marketable securities of $397.6 million, compared to $380.7 million as of March 31, 2022. We have updated our current operating plan with the receipt of $39.2 million in net proceeds raised under our ATM; the focusing and reduction in the scope of our partnered programs; a proactive pipeline prioritization and the implementation of increased operational efficiencies. Morphic believes its cash, cash equivalents and marketable securities as of June 30, 2022, will be sufficient to fund operating expenses and capital expenditure requirements into the second half of 2025.

08:00 EDT Valaris says Chris Weber commences role as SVP, CFO - Valaris Limited announced that Chris Weber has commenced his role as Senior Vice President and CFO, having been appointed to the role in late May. Chris Weber previously served as CFO of LUFKIN Industries.

07:56 EDT Stack Capital's Omio enters partnership with Uber - Stack Capital Group announces that Omio has partnered with Uber Technologies to provide its users with the opportunity to seamlessly book train and coach travel within the Uber app. The partnership will initially launch in the United Kingdom and will enable Uber users to gain access into Omio's unique inventory and proprietary technology to provide a seamless, digital, and mobile-first approach to travel including more than 1,000 transportation providers in 37 countries worldwide, hosted entirely within the Uber platform. This partnership follows Omio's most recent funding round, in which Stack Capital participated in a $80 million financing to strengthen its position as the leading ground transportation platform.

07:52 EDT NFI Group reaffirms Fiscal 2025 longer-term targets - Management also reaffirms its Fiscal 2025 longer-term targets, originally announced in January 2021, to deliver $3.9 billion to $4.1 billion in revenue, Adjusted EBITDA of $400 million to $450 million, with approximately 40% of vehicle sales coming from zero-emission vehicles, and ROIC of higher than 12%. These targets are driven by several factors and expectations, including the recovery of supply chains and other COVID-19-related impacts, a higher percentage of ZEB sales (which provide a higher revenue and dollar margin benefit), the mitigation of inflationary pressures, end markets recovery to pre-pandemic levels, realization of NFI Forward initiatives driving volume leverage, growth of cutaway and medium-duty products, aftermarket expansion, and continuous improvement initiatives.

07:50 EDT NFI Group sees 'significant' revenue, adjusted EBITDA growth from 2023-2025 - In response to a specific microprocessor shortage impacting NFI's North American manufacturing business, as detailed in the Company's 2022 Q1 financial results, NFI has been building and holding a number of vehicles in inventory. This has grown inventory by $57 million on a temporary basis. NFI continues to have detailed discussions with the microprocessor supplier and fully expects to receive the required modules to meet NFI's latest guidance. Delivery of these vehicles is expected to occur in the third and fourth quarters of 2022. Some deliveries may, however, occur in the first quarter of 2023 due to the complexity of customer delivery acceptance processes. In addition, NFI continues to work with other suppliers and microprocessor sources to assist in production recovery plans and future sourcing alternatives. Significant progress has been made on a new alternative microprocessor module that will be installed in some vehicles, helping to lower the risk of future supply disruptions. Given NFI's expectations that supply impacts continue to be temporary and based on the strong signs of market recovery in all of NFI's end markets, any cost and capital reductions will be balanced with the ability to continue to secure new orders, invest in new product development, and deliver on existing customer orders. NFI is experiencing significantly increased inflation with respect to supplier pricing and wages, and through raw material commodities purchased directly by NFI. The majority of the impacts from inflation are expected to be seen in 2022 results due to legacy firm order contracts, and these impacts are reflected in NFI's financial guidance. Newer contracts are being priced to reflect current input costs and future options contracts generally have clauses where a government purchase price index will be applied. For contracts where NFI has significant inflation exposure, the Company is seeking price increases and surcharges through negotiations with customers and surcharge letters. The Company has experienced success with these efforts and expects they will help offset some of the margin pressure facing the Company. NFI's financial guidance reflects the adverse impacts of inflation, with improved margins anticipated in 2023. While these issues are anticipated to be near-term headwinds, NFI's longer-term outlook remains strong based on its backlog and broader market conditions. NFI has received significant new orders over the past twelve months that support the Company's plan to increase headcount, and ramp-up production late in 2022 and into 2023. The Company anticipates that it will be able to source the labor required to drive higher production and volume deliveries in 2023. These new orders, combined with existing backlog, other recent bid activity, and continuing growth in government investments in transportation, are expected to drive significant revenue and Adjusted EBITDA growth for NFI from 2023 to 2025.

07:49 EDT Marcus reinstates quarterly dividend - On July 29, 2022, the Board of Directors of The Marcus Corporation declared a regular quarter cash dividend of $0.05 per share of common stock, to be paid September 15, 2022, to shareholders of record on August 25, 2022. The Board of Directors also declared a dividend of $0.045 per share of Class B common stock, to be paid September 15, 2022, to shareholders of record as of August 25, 2022.

07:48 EDT NFI Group expects to achieve $67M Adjusted EBITDA savings target by end of 2022 - In 2022 Q2, NFI Forward realized Adjusted EBITDA savings of approximately $15 million and $1 million of additional Free Cash Flow savings. The Company expects to achieve its target of $67 million in Adjusted EBITDA savings by the end of Fiscal 2022, a year ahead of the original plan. With the majority of the original projects completed, the Company has implemented a series of additional projects called "NFI Forward 2.0", that are expected to generate additional annualized Adjusted EBITDA savings in 2023 and beyond. NFI Forward 2.0 includes the integration of its Delaware parts distribution facility into its existing NFI Parts footprint during the third quarter of 2022, and a plan to close the MCI coach manufacturing facility in Pembina, North Dakota, by the end of 2022. NFI Forward 2.0 will be smaller in scale and financial impact when compared to the original NFI Forward initiatives. In total, the Company believes NFI Forward 2.0 will generate $5 million to $8 million in annual savings from one-time capital investments of $8 million to $10 million.

07:46 EDT CorVel announces new data on impact of COVID-19 on workers' claims - CorVel Corporation recently published a white paper analyzing the impact that COVID-19 had on workers' compensation claims in 2021. These strategic insights demonstrate an overall increase in claims in 2021 by 6% compared to 2020, with COVID-19 claims decreasing 38% and non-COVID claims increasing 14%. "As we enter our third year of the pandemic, it is import to look back and examine how COVID-19 impacted workers' compensation claims," said Michael Combs, President and CEO at CorVel. "Last year was a transition year for all of us, as seen in our analysis. While COVID claims declined, industries returning to work saw an increase in non-COVID claims as new and returning employees rejoined the workforce. With our CogencyIQ team and our access to extensive data, we provide these insights to our customers and colleagues, helping them to better understand the past and prepare for the future."

07:42 EDT Equifax Canada expands Financial Data Exchange engagement - Equifax Canada is deepening its commitment to promote a consent-based approach to open banking and educating Canadians on consumer-led banking by expanding its engagement with Financial Data Exchange. A member of FDX since 2020, Equifax Canada's Chief Data Officer, Sandy Kyriakatos, has been appointed to the non-profit organization's board of directors. FDX is dedicated to unifying the financial industry around a common set of open banking standards. As a non-FI member of FDX, Equifax has a unique ability to bring the industry together given its work with both Financial Institutions and Fintechs in Canada. On August 4, 2021, the Department of Finance released the Advisory Committee on Open Banking's final report, recommending that Canada move forward with open banking and implement it by January 2023. Open banking, a framework where banks enable permissioned sharing of client data with other institutions, holds the promise of providing Canadians with richer and more inclusive banking experiences, but there's a significant challenge.

07:40 EDT Pilgrim's Pride releases 2021 Sustainability Report - Pilgrim's announced the release of its 2021 Sustainability Report, which includes progress updates toward the organization's 2030 goals that were announced last year. The report details the company's advancements in critical areas - team members, environment, communities, animal care, customers and consumers, and suppliers - across its operations in the United States, the UK, Continental Europe and Mexico. As Pilgrim's continues to strengthen its approach toward sustainability and ESG, the company completed its first sustainability-linked bond audit, resulting in positive progress toward the commitment to achieve a 30 percent reduction in scope 1 and scope 2 greenhouse gas emission intensity by 2030. The newly-created Pilgrim's Pride ESG Committee of the Pilgrim's Board of Directors was also developed, which has been tasked with overseeing areas such as climate change, human rights, diversity and inclusion, and employee health, safety and well-being to ensure excellence, humanity and corporate responsibility are fully integrated in every level of the organization. "At Pilgrim's, we recognize our role as a global food company and a large employer in the areas where we operate," said Fabio Sandri, CEO, Pilgrim's. "We are working to leverage our scale and influence to help food and agriculture be part of the solution to many of the sustainability challenges we face around the world."

07:38 EDT Moderna sees FY22 CapEx $600M-$800M - For FY22: Cost of sales as percentage of product sales are expected to be in the mid- 20s percentage range, with possible cost of sales in the high-20s in the event of further charges due to product updates. Full year expenses are expected to be approximately $4B. The company expects an effective tax rate for the full year in the low- to mid-teen percentage range.

07:36 EDT Moderna backs advance purchase agreements for expected delivery in 2022 of $21B - "Moderna's APAs for product sales for which we expect to make delivery in 2022 are approximately $21 billion. This includes the recently announced agreement with the U.S. government for 70 million doses (option for 4 million pediatric doses has been exercised) and an adjustment for doses that remain unallocated by COVAX due to lack of demand. Moderna anticipates that for sales in the second half, sales will be greater in the fourth quarter than the third quarter, driven by the timing for approval of our updated COVID-19 vaccines and the related manufacturing ramp-up of new products."

07:35 EDT Moderna announces new $3B share repurchase plan - "Today's earnings represent a strong second quarter performance, with $10.8 billion in revenue for the first half of the year. We continue to have advance purchase agreements for expected delivery in 2022 of around $21 billion of sales. Given our strong financial position and commercial momentum, we are announcing today that the Board of Directors has approved a new share repurchase program for $3 billion," said Stephane Bancel, CEO of Moderna. "Despite the slowing economy and challenges in the biotech industry, Moderna is in a unique position: a platform to drive scale and speed in research of new medicines, a strong balance sheet of $18 billion of cash and an agile, mission-driven team of over 3,400 people and growing. We will continue to invest and grow as we have never been as optimistic about Moderna's future. Right now, we have four infectious disease vaccines in Phase 3 trials, and later this year, we expect important data from proof-of-concept studies in rare diseases and immuno-oncology. Our teams are actively working to prepare these new product launches to help patients and drive growth. This is an exciting time for Moderna as we continue to see significant scientific and business momentum."

07:33 EDT Stratasys sees Q3 gross margins relatively flat vs. last year - Based on current logistics and materials costs, sees third quarter gross margins relatively flat compared to third quarter of 2021, and full-year gross margins of flat to slightly higher than 2021.

07:29 EDT HCW Biologics announces US issued patent for platform technology - HCW Biologics was granted U.S. Patent 11,401,324 which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains on a scaffold made of an extracellular domain of human tissue factor. This patent provides intellectual property protection for the lead drug candidate, HCW9302, a single-chain, IL-2-based fusion protein designed to activate and expand regulatory T cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete. Hing Wong, Ph.D., Founder and CEO of HCW Biologics, expressed his excitement upon reaching this milestone by stating, "We are thrilled to announce the issuance of a patent that has allowed such broad claims. The issuance of our first patent marks an important step in the evolution of our patent portfolio. This news, along with our progress in the prosecution of our other patent applications, reinforces our belief that our novel single-chain and multi-chain immunotherapeutics, as well as the proprietary approach used to create them with our TOBI(TM) discovery platform, are novel, valuable assets. We are pleased that this patent has been granted by the U.S. Patent and Trademark Office, providing vital recognition and protection of the intellectual property on which we based one of our lead product candidates, HCW9302."

07:26 EDT Nurix Therapeutics appoints Schlezinger as CPO - Nurix Therapeutics announced that Eric Schlezinger, J.D. has joined the company as chief people officer, CPO. Schlezinger is an industry veteran with experience leading and developing human resources at high-growth private and public biopharma companies. Most recently, Mr. Schlezinger was head of Human Resources at Adamas Pharmaceuticals, a commercial-stage pharmaceutical company.

07:24 EDT Bioventus receives FDA 510(k) clearance for SonaStar Elite - Bioventus announced the US Food and Drug Administration has granted 510(k) clearance for the company's neXus SonaStar Elite handpiece. The SonaStar Elite handpiece is powered by the neXus Ultrasonic Surgical Aspirator System, a next generation integrated ultrasonic surgical platform driven by a proprietary digital algorithm resulting in more versatility and control. The neXus system combines all the features of soft and hard tissue removal into a single fully integrated platform capable of operating at multiple frequencies, including the newly approved 36 kHz SonaStar Elite Handpiece. While the neXus system can be used in many clinical applications including neurosurgery, the SonaStar Elite handpiece has been cleared for resection of tumors with varying consistencies ranging from soft to firm, including the removal of malignant and benign brain and spinal tumors.

07:21 EDT TCR Acquisition responds to Kaleyra filing on alien ownership - TCR Acquisition issued the following statement in response to Kaleyra, Inc.'s July 25, 2022 "Regulation FD" filing with the U.S. Securities and Exchange Commission. In that filing, Kaleyra stated that it is "confident" that it is in compliance with the regulations and other laws administered by the Committee on Foreign Investment in the United States. According to Frederick Joyce, C.E.O. and General Counsel of TCR Acquisition, "[t]here is only one way to safely determine if Kaleyra's ownership of The Campaign Registry complies with CFIUS and the Foreign Investment Risk Review Modernization Act, and that is to have this matter reviewed by appropriate federal authorities, not by Kaleyra's executives and its paid attorneys. If Kaleyra's board and senior officers are confident that they have complied with CFIUS and other alien ownership requirements in the U.S., then they should be willing to submit this matter to U.S. governmental review. The Campaign Registry is the exclusive vendor used by all nationwide mobile telephone companies to verify who sends text messages and what is contained in text messages sent to mobile phones used by U.S. customers. This registry is responsible for screening billions of text messages sent to U.S. mobile phones every month. The senders of these text messages include public law enforcement and safety officials, state and federal election campaigns, not for profit organizations, and thousands of commercial entities. Increasingly, political campaigns around the country at all levels - from school boards to the U.S. Senate and the Presidency - are relying on text messaging as a convenient means of connecting and communicating directly with voters and supporters. The Campaign Registry plays a crucial role in authenticating and protecting these increasingly important communication channels. Public confidence in the integrity of The Campaign Registry is essential for maintaining and bolstering confidence in the electoral process. It is therefore particularly concerning that foreign ownership and interests could put a thumb on the scale of information flow - or could distort or bias these communication channels in favor of unknown or foreign goals. With 2022 federal election campaigns already in progress, and to ensure the integrity of the 2024 Presidential campaigns, it is critical that The Campaign Registry be owned by a transparent, U.S.-owned and operated entity."

07:18 EDT Tradeweb Markets backs FY22 adjusted expense view $620M-$655M - Still sees FY22 CapEx and capitalization of software development $62M-$68M.

07:16 EDT Farmland Partners acquires two Illinois farms totaling 485 acres - Farmland Partners announced the acquisition of two Illinois farms totaling 485 acres. The first, a 286-acre farm in Edgar County, was purchased for approximately $4.8M on July 29. FPI also bought a 199-acre farm in Fulton County on August 1 for $1.8M. "These farms are especially attractive to our business because they adjoin other farmland in our portfolio, which will allow the Company to expand its footprint in these areas, improve farming efficiency for our tenants, and drive strong rental rates," said FPI Chairman and CEO Paul Pittman. In addition to rental income, Pittman noted that asset appreciation is a key factor of overall farmland investment returns. Illinois farmland averaged 5.6% in annual appreciation from 1970-2021, according to the U.S. Department of Agriculture. FPI has acquired 11 farms in 2022, spanning 3,056 acres. It is the nation's largest publicly traded farmland REIT by U.S. acreage.

07:14 EDT McDermott, KBR enter global licensing agreement for ammonia - McDermott International and KBR have entered into a global licensing agreement to provide integrated solutions for KBR's proprietary ammonia technologies. Ammonia produced from renewable or low-carbon sources, commonly referred to as green and blue ammonia, supports global decarbonization because it can be used to provide carbon-free fertilizers, as an energy carrier or as a fuel. The agreement represents a compelling solution to meet the growing ammonia market which combines KBR's leading technology with McDermott's global execution capabilities and fabrication and modularization expertise. As part of the agreement, McDermott and KBR will jointly evaluate opportunities to provide modularized execution concepts to drive additional efficiencies tailored to the needs of green and blue ammonia projects.

07:14 EDT Pebblebrook Hotel closed Sofitel sale in Philadelphia - Pebblebrook Hotel Trust announces that on August 2, it closed on the sale of the 306-room Sofitel Philadelphia at Rittenhouse Square in Philadelphia, PA for $80M to a third party. For the trailing twelve months ended June 30 the hotel's net operating income was $3.1M and its Hotel EBITDA was $3.8 million. Based on the hotel's operating performance for 2019, the $80.0 million sales price reflects a 10.0x EBITDA multiple and an 8.6% net operating income capitalization rate. The net operating income for both periods mentioned above is after an assumed annual capital reserve of 4.0% of total hotel revenues. Proceeds from the sale of Sofitel Philadelphia at Rittenhouse Square will be used for general corporate purposes and reducing the Company's outstanding debt borrowings associated with recent hotel acquisitions, in accordance with the Company's investment strategy.

07:13 EDT EVgo's PlugShare surpasses 5M check-ins - PlugShare, a part of the EVgo Inc. family since mid-2021, today announced that the platform has surpassed five million check-ins worldwide. With more than 600,000 charging stations listed on the platform, PlugShare's announcement comes on the heels of its recent user milestone of reaching over two million registered users globally. As part of this rapid growth, the number of stations featured on the PlugShare app increased by 50% over the last year, the company said.

07:12 EDT MarketAxess announces July total trading average daily volume $31.1B - Reports $31.1B in total trading average daily volume, up 31%, driven by a 49% increase in U.S. Treasury ADV to $20.3B and an 8% increase in total credit ADV to $10.6B. The preliminary average fee per million for total credit was $166 per million in July, in-line with $166 per million in the second quarter of 2022

07:11 EDT Senseonics announces positive coverage decision for Eversense E3 CGM from Anthem - Senseonics Holdings announced that Anthem is providing coverage for implantable CGM, which includes the Eversense CGM System. Anthem's decision will add more than 45 million covered lives for the long-term implantable CGM system to help manage their diabetes. This recent coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies that now benefit approximately 250 million covered lives, as well as paying for the healthcare provider's time for the in-office sensor insertion. This allows Ascensia Diabetes Care, Senseonics' global commercial partner, to introduce the Eversense CGM System to more people living with diabetes. Anthem is the second largest health insurance company in the U.S. and a leading health company dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Anthem serves people across 14 states, including more than 45 million within its family of health plans. This most recent coverage decision, in addition to Cigna, Aetna, Humana, HCSC Blue Cross Blue Shield and other health insurance providers, demonstrates broad-based coverage across the United States from the majority of commercial payers, enabling their members to access the benefits of the long-term Eversense CGM System. "Anthem is dedicated to delivering better care to its members and improving the health of the communities it serves. We are excited for Anthem members to have the ability to effectively manage their diabetes through the only long-term implantable CGM system available," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "Eversense provides patients with actionable glucose data, enabling users to proactively manage their glucose levels. With its six month sensor life, sustained accuracy, on-body vibratory alerts and remote monitoring capability, Eversense E3 offers patients an advanced CGM to help effectively manage their diabetes and experience healthier outcomes."

07:09 EDT Scotts Miracle-Gro launches Project Springboard to strengthen balance sheet - The Company announced Project Springboard, a cross-functional initiative to expand margins, improve cash flow and strengthen the balance sheet to provide a solid foundation for sustainable shareholder value creation.

07:07 EDT Yum! Brands reports Q2 SSS ex-China up 6% - Reports Q2 SSS for KFC down 1%, ex-China up 7%; U.S. Taco Bell SSS up 8% and International Taco Bell up 9%; Pizza Hut SSS down 3%.

07:03 EDT Ceragon Networks confirms receipt of revised proposal from Aviat Networks - Ceragon Networks (CRNT) confirmed that it has received a revised non-binding indication of interest from Aviat Networks (AVNW) to acquire all of the outstanding shares of Ceragon for $3.08 per share, consisting of $2.80 in cash and $0.28 in equity consideration of Aviat common stock, subject to certain conditions. The Ceragon Board of Directors, consistent with its fiduciary duties and in consultation with its independent financial and legal advisors, will carefully review and evaluate the Revised IOI to determine the course of action it believes is in the best interest of the company and its shareholders.

07:03 EDT EyePoint exoects cash to fund operations into second half of 2024 - The company expect the cash, cash equivalents and investments on hand on June 30, 2022 and expected net cash inflows from its product sales will enable it to fund its current and planned operations into the second half of 2024.

06:57 EDT ANI Pharmaceuticals launches Acebutolol Hydrochloride Capsules - ANI Pharmaceuticals announced the launch of Acebutolol Hydrochloride Capsules. ANI's Acebutolol Hydrochloride Capsules are the generic version of the Reference Listed Drug Sectral. The current annual U.S. market for Acebutolol Hydrochloride Capsules is approximately $10M, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.

06:49 EDT Daqo New Energy sees Q3 polysilicon production 31,000 MT-32,000 MT

06:45 EDT Denison Mines announces completion of metallurgical test on Phoenix plant - Denison Mines announces the substantial completion of extensive metallurgical test work to define the mechanical components for the planned Phoenix processing plant, as part of the Feasibility Study underway for the Company's 95% owned Wheeler River project. In addition, the metallurgical program has confirmed the ability to produce a yellowcake product that meets industry standard ASTM C967-13 specifications. Metallurgical test work intended to define the mechanical components for the Phoenix Plant was initiated in April 2021 at the Saskatchewan Research Council laboratories in Saskatoon. The results of the metallurgical test work are highlighted by the following: The UBS from the high-grade Phoenix deposit was processed using simple chemical precipitation stages to remove certain elements prior to the yellowcake precipitation circuit. A yellowcake product that meets uranium industry standard ASTM C967-13 specifications has been precipitated in the lab. A high-quality effluent was obtained using typical industrial water treatment processes through pH control and precipitation.

06:44 EDT BorgWarner acquires Rhombus Energy Solutions in $185M transaction - BorgWarner announced that it has acquired Rhombus Energy Solutions. Headquartered in San Diego, California, Rhombus offers V2G and Underwriters Laboratory-certified charging. Rhombus supplies its patented technology to EV OEMs, including Proterra, and charging and grid service providers. The transaction has an enterprise value of up to $185 million, which is being funded primarily with cash balances. Approximately $130 million was delivered at closing and up to $55 million could be paid in the form of contingent payments over the next 3 years.

06:42 EDT Merck says Phase 3 KEYNOTE-921 trial did not meet dual primary endpoints - Merck announced that the Phase 3 KEYNOTE-921 trial evaluating KEYTRUDA in combination with chemotherapy compared to chemotherapy alone did not meet its dual primary endpoints of overall survival, or OS, and radiographic progression-free survival, or rPFS, for the treatment of patients with metastatic castration-resistant prostate cancer, or mCRPC. "In the study, there were modest trends toward an improvement in both OS and rPFS for patients who received KEYTRUDA plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. Results will be presented at an upcoming medical meeting," the company stated. "Results from this study serve as an important reminder that metastatic prostate cancer remains very difficult to treat, and more research is needed. We will continue to advance our clinical development program to evaluate KEYTRUDA-based combinations and novel candidates for patients with this disease," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories.

06:29 EDT Regeneron announces initial data from Phase 1/2 trial of REGN5678 with Libtayo - Regeneron Pharmaceuticals announced initial data from an ongoing Phase 1/2 trial investigating REGN5678, a novel PSMAxCD28 costimulatory bispecific antibody, in combination with the company's PD-1 inhibitor Libtayo in advanced metastatic castration-resistant prostate cancer. REGN5678 is one of Regeneron's three clinical-stage costimulatory bispecifics, all of which are designed to bridge T cells to cancer cells and augment CD28 signaling to increase anti-tumor activity in combination with Libtayo or a CD3 bispecific. The Phase 1/2, first-in-human, open label trial is currently enrolling patients with advanced mCRPC whose tumors have previously progressed on multiple anti-androgen therapies, with a majority also having received prior chemotherapy. In the Phase 1 dose-escalation portion, patients are initiated with weekly doses of REGN5678, for three weeks, to assess the safety and efficacy of this novel costimulatory antibody alone, which then continues in combination with standard dose Libtayo. The primary endpoints are safety, tolerability and pharmacokinetics. The key secondary endpoint is objective response rate defined as a greater than or equal to50% decline of prostate-specific antigen from baseline and/or tumor shrinkage. PSA is a protein produced by the prostate gland and is commonly used as a biomarker to diagnose and follow prostate cancer, as many mCRPC patients have disease limited to bone lesions and cannot be assessed by conventional RECIST 1.1 criteria. Preliminary data from the ongoing dose-escalation portion of the trial, across 8 dose level cohorts and a total of 33 patients, showed dose-dependent anti-tumor activity per centrally collected PSA values, as well as investigator reports. Not all patients have undergone or completed tumor assessments and the data are not yet final. At the lowest dose levels, there was almost no evidence of anti-tumor activity, with only 1 of 17 patients showing a decrease in PSA; there were no greater than or equal tograde 3 immune-related adverse events at these doses. The lack of anti-tumor activity among these patients was consistent with the approximate 6% response rate reported in other trials with anti-PD1 monotherapy. At the next three dose levels, evidence of dose-dependent anti-tumor activity was generally seen within 6 weeks of starting combination treatment as follows: Cohort 6: 1 of 4 patients experienced a 100% decrease in PSA and a complete response in target lesions based on RECIST 1.1 criteria. The patient discontinued therapy due to a Gr3 irAE of the skin. The patient has maintained the 100% decrease in PSA and CR in target lesions for approximately 10 months to date per investigator report. Cohort 7: 3 of 8 patients experienced decreases in PSA of greater than99%, 44% and 22%. Two of these three patients had a Gr3 AE. Cohort 8: 3 of 4 patients experienced decreases in PSA of greater than99%, greater than99% and 82%. Of the two patients with greater than99% PSA reductions, one experienced a Gr3 case of mucositis and the other experienced a Gr3 case of acute inflammatory demyelinating polyradiculopathy. In terms of safety, no greater than or equal toGr3 irAEs were observed in patients without anti-tumor activity, and the occurrence of irAEs was correlated with anti-tumor activity; this is consistent with previous trials with anti-PD-1 immunotherapy, wherein irAEs have been reported to occur at a higher rate in responding patients. No Gr4 irAEs or greater than or equal toGr2 cytokine release syndrome have been observed in the trial to date. There was one death that was considered unrelated to treatment. In this trial, irAEs are being treated according to standard management practices used for checkpoint inhibitors. Additional data are planned for presentation at an upcoming medical meeting. The combination of REGN5678 and Libtayo is currently under clinical development for mCRPC, and its safety and efficacy have not been fully evaluated by any regulatory authority.

06:18 EDT Bright Scholar completes redemption of remaining outstanding senior notes - Bright Scholar Education Holdings announced that it has redeemed all of its outstanding senior notes matured on July 31, 2022. The redemption price included the principal amount of all outstanding Senior Notes of $223,984,000 and the interest of $8,343,404 accrued till the day before the Maturity Date. The redemption price paid by the Company on the Maturity Date is $232,327,404. The Company believes the Redemption will not have an adverse and material impact on its financial position. Upon the completion of the Redemption, all senior notes have been cancelled and delisted from the official list of the Hong Kong Stock Exchange.

06:11 EDT Nintendo sold 3.43M Switch consoles in Q1 vs. 4.45M last year - Nintendo said: "Hardware sales for the quarter totaled 3.43 million units and software sales totaled 41.41 million units. However, due to the effects of supply shortages in semiconductors and other components among other factors, hardware sales were down 22.9% year-on-year, and software sales were down 8.6% year-on-year."

06:09 EDT Dorian LPG board declares irregular cash dividend of $1.00 per share - Dorian LPG reported its financial results for the three months ended June 30, 2022, and announced that its Board of Directors has declared an irregular cash dividend of $1.00 per share of the Company's common stock, returning over $40.1 million of capital to shareholders. The dividend is payable on or about September 2, 2022 to all shareholders of record as of the close of business on August 15, 2022.

05:55 EDT Match Group announces departure of Tinder CEO Renate Nyborg - Match Group announced yesterday the departure of Tinder CEO Renate Nyborg. CEO Bernard Kim said: "I have made some changes to the management team and structure that I am confident will help deliver Tinder's full potential. While we search for a permanent Tinder CEO, I will oversee a newly formed team of executives who will manage day-to-day operations and will ensure the Tinder organization is well coordinated, ships great new features at increased velocity and delivers on Tinder's promise. I'll be fully embedded within the team at our main Tinder office in LA to oversee business progress until the search is complete."

05:48 EDT Ipsen: Phase III RESILIENT trial did not meet primary endpoint of OS - Ipsen announced that the Phase III RESILIENT trial did not meet its primary endpoint of overall survival compared to topotecan. The trial is evaluating Onivyde versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy treatment. RESILIENT is a Phase III trial conducted in two parts; the first part read out in 2020 confirming the safety, dosing and efficacy of Onivyde; part two is evaluating the efficacy of Onivyde versus topotecan. Detailed results from the RESILIENT trial will be presented at an upcoming medical conference. The analysis concluded that the primary endpoint OS was not met in patients treated with Onivyde versus topotecan. However, a doubling of the secondary endpoint of objective response rate in favor of Onivyde was observed. The safety and tolerability of Onivyde was consistent with its already-known safety profile, and no new safety concerns emerged. The clinical study results will be communicated with the regulatory agency.